Fig. 1

ALKBH5 expression is downregulated in gemcitabine-treated PDX pancreatic cancer. ALKBH5 expression is downregulated in gemcitabine (Gem)-treated-patient-derived xenograft (PDX). a Schematic representation of the gemcitabine (Gem)-treated-patient-derived xenograft (PDX) approach. b Immunoblotting to measure the expression of N⁶-methyladenosine (m⁶A) demethylases (ALKBH5 and FTO) and methyltransferase complex composed of METTL3, METTL14, WTAP, VIRMA and RBM15, in cells isolated from PDX mice of 2 passages treated with saline (control) or gemcitabine. c Quantification of (b). d Representative images of immunohistochemistry staining for ALKBH5 in tumor tissue from PDX treated with control or gemcitabine. H&E, hematoxylin and eosin. e and (f) Gene expression of ALKBH5 in human PDAC compared to normal tissues from 2 GEO data sets. g ALKBH5 expression in PDAC tissues compared with paired adjacent tissues in 57 patients (h) Kaplan-Meier analysis indicating overall survival of PDAC patients with high (red) (n = 94) or low (black) (n = 83) ALKBH5 expression.  Scale bar = 200 μm in d. The data are shown as the means ± S.D. *P < 0.05; **P <0.01